American gastroenterological association institute technical review on the pharmacological management of irritable bowel syndrome

Gastroenterology

Volumn 147, Issue 5, 2014, Pages 1149-1172.e2

  Chang, Lin ^a   Lembo, Anthony ^b   Sultan, Shahnaz ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MACROGOL; PLACEBO; RIFAXIMIN; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; GASTROINTESTINAL AGENT;

HEALTH CARE ORGANIZATION; HUMAN; IRRITABLE COLON; MEDICAL INFORMATION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; COMPLICATION; CONSTIPATION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; IRRITABLE BOWEL SYNDROME; STANDARDS; TREATMENT OUTCOME; UNITED STATES;

CONSTIPATION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GASTROENTEROLOGY; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; TREATMENT OUTCOME; UNITED STATES;

EID: 84908274811     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.09.002     Document Type: Article

References (99)

1. G.F. Longstreth, W.G. Thompson, and W.D. Chey Functional bowel disorders Gastroenterology 130 2006 1480 1491
2. R.M. Lovell, and A.C. Ford Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis Am J Gastroenterol 107 2012 991 1000
3. A.P. Hungin, L. Chang, and G.R. Locke Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact Aliment Pharmacol Ther 21 2005 1365 1375
4. A.P. Hungin, P.J. Whorwell, and J. Tack The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects Aliment Pharmacol Ther 17 2003 643 650
5. D.A. Drossman, M. Camilleri, and E.A. Mayer AGA technical review on irritable bowel syndrome Gastroenterology 123 2002 2108 2131
6. P. Pare, J. Gray, and S. Lam Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study Clin Ther 28 2006 1726 1735 discussion 1710-1711
7. J. Hammer, G.D. Eslick, and S.C. Howell Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia Gut 53 2004 666 672
8. S.J. Vanner, W.T. Depew, and W.G. Paterson Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome Am J Gastroenterol 94 1999 2912 2917
9. T. Dassopoulos, J.M. Inadomi, and J.D. Lewis The development of clinical guidelines by the American Gastroenterological Association Gastroenterology 138 2010 417 418
10. J.M. Inadomi, and D.S. Weinberg How to recognize a good guideline Gastroenterology 145 2013 1179 1181
11. S. Sultan, Y. Falck-Ytter, and J.M. Inadomi The AGA institute process for developing clinical practice guidelines part one: grading the evidence Clin Gastroenterol Hepatol 11 2013 329 332
12. G.H. Guyatt, A.D. Oxman, and G. Vist GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias) J Clin Epidemiol 64 2011 407 415
13. G.H. Guyatt, A.D. Oxman, and S. Sultan GRADE guidelines: 9. Rating up the quality of evidence J Clin Epidemiol 64 2011 1311 1316
14. G.H. Guyatt, A.D. Oxman, and H.J. Schunemann GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology J Clin Epidemiol 64 2011 380 382
15. G.H. Guyatt, A.D. Oxman, and V. Montori GRADE guidelines: 5. Rating the quality of evidence - publication bias J Clin Epidemiol 64 2011 1277 1282
16. G.H. Guyatt, A.D. Oxman, and R. Kunz GRADE guidelines: 7. Rating the quality of evidence - inconsistency J Clin Epidemiol 64 2011 1294 1302
17. G.H. Guyatt, A.D. Oxman, and R. Kunz GRADE guidelines: 8. Rating the quality of evidence - indirectness J Clin Epidemiol 64 2011 1303 1310
18. G.H. Guyatt, A.D. Oxman, and R. Kunz GRADE guidelines 6. Rating the quality of evidence - imprecision J Clin Epidemiol 64 2011 1283 1293
19. G.H. Guyatt, A.D. Oxman, and R. Kunz GRADE guidelines: 2. Framing the question and deciding on important outcomes J Clin Epidemiol 64 2011 395 400
20. G.H. Guyatt, K. Thorlund, and A.D. Oxman GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes J Clin Epidemiol 66 2013 173 183
21. G.H. Guyatt, A.D. Oxman, and H.J. Schunemann GRADE guidelines - an introduction to the 10th-13th articles in the series J Clin Epidemiol 66 2013 121 123
22. G.H. Guyatt, A.D. Oxman, and N. Santesso GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes J Clin Epidemiol 66 2013 158 172
23. G. Guyatt, A.D. Oxman, and S. Sultan GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes J Clin Epidemiol 66 2013 151 157
24. M. Brunetti, I. Shemilt, and S. Pregno GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence J Clin Epidemiol 66 2013 140 150
25. J.C. Andrews, H.J. Schunemann, and A.D. Oxman GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength J Clin Epidemiol 66 2013 726 735
26. J. Andrews, G. Guyatt, and A.D. Oxman GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations J Clin Epidemiol 66 2013 719 725
27. S.J. Lewis, and K.W. Heaton Stool form scale as a useful guide to intestinal transit time Scand J Gastroenterol 32 1997 920 924
28. Guidance for industry: irritable bowel syndrome-clinical evaluation of drugs for treatment. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) 2012. Available at http://www.fda.gov/downloads/drugs/guidances/ucm205269.pdf.
29. D.A. Redelmeier, G.H. Guyatt, and R.S. Goldstein Assessing the minimal important difference in symptoms: a comparison of two techniques J Clin Epidemiol 49 1996 1215 1219
30. D. Thomson, K. Russell, and L. Becker The evolution of a new publication type: steps and challenges of producing overviews of reviews Res Synth Method 1 2010 198 211
31. Review Manager (RevMan) version 5.1 2011 The Nordic Cochrane Center, The Cochran Collaboration Copenhagen, Denmark
32. A.P. Bryant, R.W. Busby, and W.P. Bartolini Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract Life Sci 86 2010 760 765
33. V. Andresen, M. Camilleri, and I.A. Busciglio Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome Gastroenterology 133 2007 761 768
34. J. Castro, A.M. Harrington, and P.A. Hughes Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate Gastroenterology 145 2013 1334 1346 e1-11
35. E.J. Videlock, V. Cheng, and F. Cremonini Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis Clin Gastroenterol Hepatol 11 2013 1084 1092.e3 quiz e68
36. W.D. Chey, A.J. Lembo, and B.J. Lavins Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Am J Gastroenterol 107 2012 1702 1712
37. S. Rao, A.J. Lembo, and S.J. Shiff A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation Am J Gastroenterol 107 2012 1714 1724 quiz 1725
38. J.M. Johnston, C.B. Kurtz, and J.E. Macdougall Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation Gastroenterology 139 2010 1877 1886.e2
39. D.L. Patrick, D.A. Drossman, and I.O. Frederick Quality of life in persons with irritable bowel syndrome: Development of a new measure Dig Dis Sci 43 1998 400 411
40. J.E. Macdougall, J.M. Johnston, and B.J. Lavins An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide phase 3 clinical trials Neurogastroenterol Motil 25 2013 481 486
41. B.E. Lacy, A.J. Lembo, and J.E. Macdougall Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C Neurogastroenterol Motil 26 2014 326 333
42. D.A. Drossman, L. Chang, and N. Bellamy Severity in irritable bowel syndrome: a Rome Foundation Working Team report Am J Gastroenterol 106 2011 1749 1759 quiz 1760
43. B. Spiegel, A. Strickland, and B.D. Naliboff Predictors of patient-assessed illness severity in irritable bowel syndrome Am J Gastroenterol 103 2008 2536 2543
44. B.M. Spiegel, I.M. Gralnek, and R. Bolus Clinical determinants of health-related quality of life in patients with irritable bowel syndrome Arch Intern Med 164 2004 1773 1780
45. D.A. Drossman, L. Chang, and S. Schneck A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity Dig Dis Sci 54 2009 1532 1541
46. M. Camilleri, A.E. Bharucha, and R. Ueno Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers Am J Physiol Gastrointest Liver Physiol 290 2006 G942 G947
47. D.A. Drossman, W.D. Chey, and J.F. Johanson Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies Aliment Pharmacol Ther 29 2009 329 341
48. J.F. Johanson, D.A. Drossman, and R. Panas Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation Aliment Pharmacol Ther 27 2008 685 696
49. W.D. Chey, D.A. Drossman, and J.F. Johanson Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation Aliment Pharmacol Ther 35 2012 587 599
50. R.W. Chapman, V. Stanghellini, and M. Geraint Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome Am J Gastroenterol 108 2013 1508 1515
51. A.C. Ford, P. Moayyedi, and B.E. Lacy American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation Am J Gastroenterol 109 Suppl 1 2014 S2 S26 quiz S27
52. M. Pimentel, W. Morales, and K. Chua Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects Dig Dis Sci 56 2011 2067 2072
53. M. Pimentel, A. Lembo, and W.D. Chey Rifaximin therapy for patients with irritable bowel syndrome without constipation N Engl J Med 364 2011 22 32
54. S.B. Menees, M. Maneerattannaporn, and H.M. Kim The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis Am J Gastroenterol 107 2012 28 35 quiz 36
55. A. Lembo, S.F. Zakko, and N.L. Ferreira Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long-term sustained response (T1390) Gastroenterology 134 suppl 1 2008 A-545
56. M. Pimentel, S. Park, and J. Mirocha The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial Ann Intern Med 145 2006 557 563
57. A.I. Sharara, E. Aoun, and H. Abdul-Baki A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence Am J Gastroenterol 101 2006 326 333
58. Efficacy and Safety of Repeat Treatment with Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): Results of the TARGET 3 Study Lembo, Pimentel, Rao, Schoenfeld, Cash, Weinstock, Golden, Paterson, Bortey, Forbes, American Journal of Gastroenterology, 109 (10) abstract.
59. J.M. Jarcho, L. Chang, and M. Berman Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study Aliment Pharmacol Ther 28 2008 344 352
60. K. Tong, J.P. Nicandro, and R. Shringarpure A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program Therap Adv Gastroenterol 6 2013 344 357
61. M. Camilleri, E.A. Mayer, and D.A. Drossman Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist Aliment Pharmacol Ther 13 1999 1149 1159
62. M. Camilleri, A.R. Northcutt, and S. Kong Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial Lancet 355 2000 1035 1040
63. K.D. Bardhan, G. Bodemar, and H. Geldof A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome Aliment Pharmacol Ther 14 2000 23 34
64. M. Camilleri, W.Y. Chey, and E.A. Mayer A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Arch Intern Med 161 2001 1733 1740
65. T. Lembo, R.A. Wright, and B. Bagby Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 96 2001 2662 2670
66. W.D. Chey, W.Y. Chey, and A.T. Heath Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 99 2004 2195 2203
67. L. Chang, V.Z. Ameen, and G.E. Dukes A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS Am J Gastroenterol 100 2005 115 123
68. R. Krause, V. Ameen, and S.H. Gordon A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS Am J Gastroenterol 102 2007 1709 1719
69. B.A. Hahn, L.J. Kirchdoerfer, and S. Fullerton Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome Aliment Pharmacol Ther 11 1997 547 552
70. F. Cremonini, J.P. Nicandro, and V. Atkinson Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS Aliment Pharmacol Ther 36 2012 437 448
71. B. Spiegel, M. Camilleri, and R. Bolus Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report Gastroenterology 137 2009 1944 1953 e1-3
72. J. Tack, M. Fried, and L.A. Houghton Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective Aliment Pharmacol Ther 24 2006 183 205
73. J. Valenzuela, J. Alvarado, and H. Cohen [Latin-American consensus document on irritable bowel syndrome] Gastroenterol Hepatol 27 2004 325 343
74. A.C. Ford, L.J. Brandt, and C. Young Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Am J Gastroenterol 104 2009 1831 1843 quiz 1844
75. F. Cremonini, S. Delgado-Aros, and M. Camilleri Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Neurogastroenterol Motil 15 2003 79 86
76. R. Spiller, Q. Aziz, and F. Creed Guidelines on the irritable bowel syndrome: mechanisms and practical management Gut 56 2007 1770 1798
77. V. Andresen, V.M. Montori, and J. Keller Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Clin Gastroenterol Hepatol 6 2008 545 555
78. B. Lavo, M. Stenstam, and A.L. Nielsen Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study Scand J Gastroenterol Suppl 130 1987 77 80
79. N. Hovdenak Loperamide treatment of the irritable bowel syndrome Scand J Gastroenterol Suppl 130 1987 81 84
80. L. Ruepert, A.O. Quartero, and N.J. de Wit Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome Cochrane Database Syst Rev 2011 CD003460
81. Bergmann M HA, Schlosser T. Therapy of irritable colon with trimipramine (Herphonal) - a controlled clinical study [Die therapie des colon irritabile mit trimipramin (Herphanol) - Eine kontrollierte studie]. Z Klin Med 1991;46:1621-1628.
82. D. Boerner, R. Eberhardt, and K. Metz Wirksamkeit ind vertraeglickkeit eines antidepressivums beim colon irritablie Therapiewoche 38 1988 201 208
83. D.A. Drossman, B.B. Toner, and W.E. Whitehead Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders Gastroenterology 125 2003 19 31
84. J. Myren, H. Groth, and S.E. Larssen The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study Scand J Gastroenterol 17 1982 871 875
85. P. Nigam, K.K. Kapoor, and C.K. Rastog Different therapeutic regimens in irritable bowel syndrome J Assoc Physicians India 32 1984 1041 1044
86. N.J. Talley, J.E. Kellow, and P. Boyce Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial Dig Dis Sci 53 2008 108 115
87. H. Vahedi, S. Merat, and S. Momtahen Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome Aliment Pharmacol Ther 27 2008 678 684
88. J.G. Vij, R.C. Jiloha, and N. Kumar Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients Indian J Psychiatry 33 1991 243 246
89. J.D. Heefner, R.M. Wilder, and I.D. Wilson Irritable colon and depression Psychosomatics 19 1978 540 547
90. T. Furukawa, H. McGuire, and C. Barbui Low dosage tricyclic antidepressants for depression Cochrane Database Syst Rev 2003 CD003197
91. A.C. Ford, N.J. Talley, and P.S. Schoenfeld Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Gut 58 2009 367 378
92. M. Grover, and D.A. Drossman Psychotropic agents in functional gastrointestinal disorders Curr Opin Pharmacol 8 2008 715 723
93. S.D. Kuiken, G.N. Tytgat, and G.E. Boeckxstaens The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study Clin Gastroenterol Hepatol 1 2003 219 228
94. U. Ladabaum, A. Sharabidze, and T.R. Levin Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome Clin Gastroenterol Hepatol 8 2010 42 48.e1
95. P.S. Masand, C.U. Pae, and S. Krulewicz A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome Psychosomatics 50 2009 78 86
96. G. Tabas, M. Beaves, and J. Wang Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial Am J Gastroenterol 99 2004 914 920
97. J. Tack, D. Broekaert, and B. Fischler A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome Gut 55 2006 1095 1103
98. I.L. Khalif, E.M. Quigley, and P.A. Makarchuk Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics) J Gastrointestin Liver Dis 18 2009 17 22
99. A.M. Su, W. Shih, and A.P. Presson Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern Neurogastroenterol Motil 26 2014 36 45